FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290960434> ?p ?o ?g. }

• W4290960434 endingPage "100552" @default.
• W4290960434 startingPage "100552" @default.
• W4290960434 abstract "The prognostic and predictive value of carbohydrate antigen 19-9 (CA 19-9) in locally advanced pancreatic cancer (LAPC) has not yet been defined from prospective randomized controlled trials (RCTs).A total of 165 LAPC patients were treated within the NEOLAP RCT for 16 weeks with multiagent induction chemotherapy [ICT; either nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin)] followed by surgical exploration of all patients without evidence of disease progression. CA 19-9 was determined at baseline and after ICT and correlated with overall survival (OS) and secondary R0 resection rate.From the NEOLAP study population (N = 165) 133 patients (81%) were evaluable for CA 19-9 at baseline and 81/88 patients (92%) for post-ICT CA 19-9 response. Median OS (mOS) in the CA 19-9 cohort (n = 133) was 16.2 months [95% confidence interval (CI) 13.0-19.4] and R0 resection (n = 31; 23%) was associated with a significant survival benefit [40.8 months (95% CI 21.7-59.8)], while R1 resected patients (n = 14; 11%) had no survival benefit [14.0 (95% CI 11.7-16.3) months, hazard ratio (HR) 0.27; P = 0.001]. After ICT most patients showed a CA 19-9 response (median change from baseline: -82%; relative decrease ≥55%: 83%; absolute decrease to ≤50 U/ml: 43%). Robust CA 19-9 response (decrease to ≤50U/ml) was significantly associated with mOS [27.8 (95% CI 18.4-37.2) versus 16.5 (95% CI 11.7-21.2) months, HR 0.49; P = 0.013], whereas CA 19-9 baseline levels were not prognostic for OS. Multivariate analysis demonstrated that a robust CA 19-9 response was an independent predictive factor for R0 resection. Using a CA 19-9 decrease to ≤61 U/ml as optimal cut-off (by receiver operating characteristic analysis) yielded 72% sensitivity and 62% specificity for successful R0 resection, whereas CA 19-9 nonresponders (<20% decrease or increase) had no chance for successful R0 resection.CA 19-9 response after multiagent ICT provides relevant prognostic and predictive information and is useful in selecting LAPC patients for explorative surgery.ClinicalTrials.govNCT02125136; https://clinicaltrials.gov/ct2/show/NCT02125136; EudraCT 2013-004796-12; https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004796-12/results." @default.
• W4290960434 created "2022-08-13" @default.
• W4290960434 creator A5005128603 @default.
• W4290960434 creator A5006886614 @default.
• W4290960434 creator A5011006455 @default.
• W4290960434 creator A5012380788 @default.
• W4290960434 creator A5015957105 @default.
• W4290960434 creator A5017172335 @default.
• W4290960434 creator A5028938155 @default.
• W4290960434 creator A5031266401 @default.
• W4290960434 creator A5035577287 @default.
• W4290960434 creator A5040615261 @default.
• W4290960434 creator A5043050716 @default.
• W4290960434 creator A5058216777 @default.
• W4290960434 creator A5060338032 @default.
• W4290960434 creator A5061674360 @default.
• W4290960434 creator A5063940692 @default.
• W4290960434 creator A5069481844 @default.
• W4290960434 creator A5070309355 @default.
• W4290960434 creator A5071888326 @default.
• W4290960434 creator A5073286593 @default.
• W4290960434 creator A5078999718 @default.
• W4290960434 creator A5088860959 @default.
• W4290960434 date "2022-08-01" @default.
• W4290960434 modified "2023-10-16" @default.
• W4290960434 title "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)" @default.
• W4290960434 cites W1530374458 @default.
• W4290960434 cites W1967744965 @default.
• W4290960434 cites W2008014332 @default.
• W4290960434 cites W2012005360 @default.
• W4290960434 cites W2042280230 @default.
• W4290960434 cites W2091119990 @default.
• W4290960434 cites W2130409622 @default.
• W4290960434 cites W2132317169 @default.
• W4290960434 cites W2344938325 @default.
• W4290960434 cites W2345822778 @default.
• W4290960434 cites W2346921980 @default.
• W4290960434 cites W2467479187 @default.
• W4290960434 cites W2557297120 @default.
• W4290960434 cites W2605286194 @default.
• W4290960434 cites W2743061229 @default.
• W4290960434 cites W2751901379 @default.
• W4290960434 cites W2770835903 @default.
• W4290960434 cites W2772770935 @default.
• W4290960434 cites W2794024065 @default.
• W4290960434 cites W2801301689 @default.
• W4290960434 cites W2837607467 @default.
• W4290960434 cites W2883560642 @default.
• W4290960434 cites W2891418088 @default.
• W4290960434 cites W2897709693 @default.
• W4290960434 cites W2941614020 @default.
• W4290960434 cites W2947955936 @default.
• W4290960434 cites W2958644749 @default.
• W4290960434 cites W2999989792 @default.
• W4290960434 cites W3000487074 @default.
• W4290960434 cites W3014175209 @default.
• W4290960434 cites W3025322003 @default.
• W4290960434 cites W3026026643 @default.
• W4290960434 cites W3085912351 @default.
• W4290960434 cites W3086844699 @default.
• W4290960434 cites W3087598614 @default.
• W4290960434 cites W3112148397 @default.
• W4290960434 cites W3121138383 @default.
• W4290960434 cites W3191282169 @default.
• W4290960434 doi "https://doi.org/10.1016/j.esmoop.2022.100552" @default.
• W4290960434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35970013" @default.
• W4290960434 hasPublicationYear "2022" @default.
• W4290960434 type Work @default.
• W4290960434 citedByCount "6" @default.
• W4290960434 countsByYear W42909604342022 @default.
• W4290960434 countsByYear W42909604342023 @default.
• W4290960434 crossrefType "journal-article" @default.
• W4290960434 hasAuthorship W4290960434A5005128603 @default.
• W4290960434 hasAuthorship W4290960434A5006886614 @default.
• W4290960434 hasAuthorship W4290960434A5011006455 @default.
• W4290960434 hasAuthorship W4290960434A5012380788 @default.
• W4290960434 hasAuthorship W4290960434A5015957105 @default.
• W4290960434 hasAuthorship W4290960434A5017172335 @default.
• W4290960434 hasAuthorship W4290960434A5028938155 @default.
• W4290960434 hasAuthorship W4290960434A5031266401 @default.
• W4290960434 hasAuthorship W4290960434A5035577287 @default.
• W4290960434 hasAuthorship W4290960434A5040615261 @default.
• W4290960434 hasAuthorship W4290960434A5043050716 @default.
• W4290960434 hasAuthorship W4290960434A5058216777 @default.
• W4290960434 hasAuthorship W4290960434A5060338032 @default.
• W4290960434 hasAuthorship W4290960434A5061674360 @default.
• W4290960434 hasAuthorship W4290960434A5063940692 @default.
• W4290960434 hasAuthorship W4290960434A5069481844 @default.
• W4290960434 hasAuthorship W4290960434A5070309355 @default.
• W4290960434 hasAuthorship W4290960434A5071888326 @default.
• W4290960434 hasAuthorship W4290960434A5073286593 @default.
• W4290960434 hasAuthorship W4290960434A5078999718 @default.
• W4290960434 hasAuthorship W4290960434A5088860959 @default.
• W4290960434 hasBestOaLocation W42909604341 @default.
• W4290960434 hasConcept C121608353 @default.
• W4290960434 hasConcept C126322002 @default.
• W4290960434 hasConcept C141071460 @default.
• W4290960434 hasConcept C143998085 @default.

• next